[
  {
    "ts": null,
    "headline": "Here’s Why You Should Consider Buying Regeneron Pharma (REGN)’s Shares",
    "summary": "Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 […]",
    "url": "https://finnhub.io/api/news?id=78f385386cd441b07fe0a4361ada123e28e9d60ddfe9c1695c731d370c208c5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755090353,
      "headline": "Here’s Why You Should Consider Buying Regeneron Pharma (REGN)’s Shares",
      "id": 136328573,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 […]",
      "url": "https://finnhub.io/api/news?id=78f385386cd441b07fe0a4361ada123e28e9d60ddfe9c1695c731d370c208c5d"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call",
    "summary": "Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial performance of Dupixent, Libtayo, and the launch of EYLEA HD. CEO Leonard Schleifer highlighted that worldwide net product sales for Dupixent increased by 21% and Libtayo by 25% at constant exchange rates, while EYLEA HD saw a 29% rise in the U.S. compared to the prior year. Management pointed to broad-based demand across new indications and geographies, as well as positi",
    "url": "https://finnhub.io/api/news?id=7e758829779db193fbc25c3a1583f9d2e79bd38fc2f335c547ec356d0d311669",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755058481,
      "headline": "5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call",
      "id": 136328574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial performance of Dupixent, Libtayo, and the launch of EYLEA HD. CEO Leonard Schleifer highlighted that worldwide net product sales for Dupixent increased by 21% and Libtayo by 25% at constant exchange rates, while EYLEA HD saw a 29% rise in the U.S. compared to the prior year. Management pointed to broad-based demand across new indications and geographies, as well as positi",
      "url": "https://finnhub.io/api/news?id=7e758829779db193fbc25c3a1583f9d2e79bd38fc2f335c547ec356d0d311669"
    }
  },
  {
    "ts": null,
    "headline": "REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was 52.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=009dde26f0ce305ac0b0fc542c6f3632051a609ff5c1c8f321692daed1bc159c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755056591,
      "headline": "REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges",
      "id": 136328575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was 52.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=009dde26f0ce305ac0b0fc542c6f3632051a609ff5c1c8f321692daed1bc159c"
    }
  }
]